MILLENNIUM PHARMACEUTICALS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1993-01-01
- Employees
- 1K
- Market Cap
- -
IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-05-09
- Last Posted Date
- 2023-07-21
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 705
- Registration Number
- NCT01850524
Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-05-01
- Last Posted Date
- 2019-03-25
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT01844583
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal Impairment
- First Posted Date
- 2013-04-12
- Last Posted Date
- 2019-06-10
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT01830816
- Locations
- 🇺🇸
Mary Crowley Cancer Research Centers Medical City, Dallas, Texas, United States
🇺🇸Institute of Oncology Hematology Biomedical Research, Laredo, Texas, United States
🇺🇸University of Kansas Cancer Center, Clinical Research Center, Fairway, Kansas, United States
Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older
- First Posted Date
- 2013-03-20
- Last Posted Date
- 2020-03-03
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT01814826
- Locations
- 🇺🇸
Hospital Corporation of America-HealthOne, LLC, Denver, Colorado, United States
🇺🇸UNC-Chapel Hill School of Medicine, Chapel Hill, North Carolina, United States
🇺🇸University of Miami School of Medicine, Miami, Florida, United States
Mass Balance, Pharmacokinetics and Metabolism Study of Alisertib
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-10-26
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT01714947
- Locations
- 🇺🇸
Comprehensive Clinical Development, Tacoma, Washington, United States
Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naive Participants With Castration-Resistant Prostate Cancer
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-08-16
- Last Posted Date
- 2018-03-20
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 137
- Registration Number
- NCT01666314
- Locations
- 🇺🇸
Urology Cancer Center, PC, Omaha, Nebraska, United States
Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2012-08-08
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 177
- Registration Number
- NCT01659658
- Locations
- 🇺🇸
Indiana University School of Medicine, Indianapolis, Indiana, United States
🇺🇸University of Cincinnati, Cincinnati, Ohio, United States
🇺🇸Tufts Medical Center, Boston, Massachusetts, United States
Phase 1 Pharmacokinetic Study of Oral Ixazomib Plus Lenalidomide and Dexamethasone in Adult Asian Participants With Relapsed and/or Refractory Multiple Myeloma
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-07-20
- Last Posted Date
- 2018-11-08
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT01645930
Study of TAK-733 in Combination With Alisertib in Adult Patients With Advanced Nonhematologic Malignancies
Phase 1
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2012-06-07
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Registration Number
- NCT01613261
- Locations
- 🇺🇸
South Texas Accelerated Research Therapeutics (START), San Antonio, Texas, United States
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-04-17
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 131
- Registration Number
- NCT01578499
© Copyright 2024. All Rights Reserved by MedPath